route=deep subcutaneous; population=healthy subjects; state=single dose; statistic=time window for mean Cmax; source_value=during the first day
Evidence role
Reported: reviewed reported observation that should not be pooled as a comparable value yet
Assay / model
human
Condition
Route: subcutaneous · Lanreotide · 6e4a41fd-a753-4362-87ee-8cc56ed3660d · 12.3 Pharmacokinetics · lanreotide single dose tmax within first day · After a single, deep subcutaneous administration, the me...
